SDGR Stock Risk & Deep Value Analysis
Schrodinger Inc
Healthcare • Health Information Services
DVR Score
out of 10
What You Need to Know About SDGR Stock
We analyzed Schrodinger Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SDGR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is SDGR Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
High
Regulatory Risk
Medium
What Are the Red Flags for SDGR?
- âš
Negative clinical trial results for any pipeline candidate (internal or partnered)
- âš
Increased R&D burn rate without proportional progress, leading to higher dilution
- âš
Loss of key software customers or inability to secure major renewals
- âš
New, highly competitive AI drug discovery platforms emerging
Unlock SDGR Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Schrodinger Inc (SDGR) Do?
Market Cap
$1.32B
Sector
Healthcare
Industry
Health Information Services
Employees
891
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Visit Schrodinger Inc WebsiteIs SDGR Stock Undervalued?
Unlock the full AI analysis for SDGR
Get the complete DVR score, risk analysis, and more
Does SDGR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
Schrödinger's moat is durable due to its highly specialized, proprietary computational platform that integrates physics-based modeling with AI/ML. This technology is difficult and expensive to replicate, offering superior accuracy and speed in drug discovery. High switching costs for pharmaceutical partners, who integrate the software deeply into their R&D workflows, further reinforce this moat. The increasing dataset generated by their platform provides continuous improvement and a network effect within the scientific community.
Moat Erosion Risks
- •Emergence of superior, easier-to-use computational drug discovery platforms from well-funded competitors
- •Failure of internal drug pipeline to generate significant value, shifting focus away from software business
- •Increased competition in specific drug targets chosen for internal development
SDGR Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive SDGR Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings on March 6, 2026 (Expected focus on software revenue and 2026 guidance)
- •Progress updates on key partnered programs (e.g., BMS, Takeda)
- •Announcement of new software licensing agreements or renewals
Medium-Term (6-18 months)
- •IND filing or initiation of Phase 1 clinical trial for internal pipeline candidates (e.g., MALT1, Wee1/PKMYT1)
- •Preclinical data readouts for earlier-stage internal programs
- •Expansion of software platform capabilities or new modules
Long-Term (18+ months)
- •Successful Phase 2 clinical trial readouts for internal or partnered drug candidates
- •Broader adoption of computational drug discovery becoming industry standard, positioning SDGR as a leader
- •Monetization events (e.g., licensing deals, royalties) from successful internal drug programs
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for SDGR?
- âś“
Acceleration in software revenue growth and ARR figures above estimates
- âś“
Successful progression of key internal pipeline assets into and through clinical trials
- âś“
Announcements of new major software partnerships or expanded collaborations
- âś“
Improvement in cash burn rate and path to profitability for the software segment
Bull Case Analysis
See what could go right with Premium
Compare SDGR to Similar Stocks
See how Schrodinger Inc stacks up against related companies in our head-to-head analysis.
đź“Š Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for SDGR (Schrodinger Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
